Supreme Court Ruling On Gene Patenting May Be A Boon For Biotech Startups

Buried in the ongoing PRISM debacle, there was actually some hopeful news out of Washington D.C. for startups this week. The Supreme Court ruled this week that naturally occurring genes can’t be patented, which should be a boon for the host of emerging gene testing and patenting companies that are coming out of the Valley. Silicon Valley VCs like Founders Fund, Khosla Ventures, Felicis Ventures and SV Angel have been making more bets in the space, on the assumption that biology is becoming a space that can be attacked by software. In the case, a company called Myriad Genetics had acquired patents on BRCA1 and BRCA2, two genes that are strongly correlated with breast and ovarian cancer. Because of their patents, the cost of testing for those genes had been pushed higher, sometimes beyond the $3,000 range. That would have made it too expensive for many middle- and low-income women to learn if they were at risk for the cancers. At the same time, other human genes were being scooped up with somewhere north of 20 percent of all human genes being covered by patents, according to the National Society of Genetic Counselors. The leading gene patent holders are unsurprisingly pharmaceutical giants like DuPont and GlaxoSmithKline, that startups would have a financially hard time competing against in courts. The court ruled that human genes can’t be patented, but that synthetic genes can be protected. Now that naturally occurring human genes can’t be patented, expect gene testing companies to benefit broadly with lower-cost products across the board. The costs for full human genome sequencing have already fallen to about $8,000 today from $100 million in 2011. One of the remaining barriers preventing lower-cost testing has been whether consumers would be on the receiving end of high licensing fees to the patent owners of these genes. Patent holders like Myriad could also monopolize the testing market for these genes too, which would have also forced prices higher. One company that I’ve written about, Counsyl, tests prospective parents for any hereditary diseases they might pass onto their children like Tay-Sachs Disease. They’ve gotten such broad adoption in medical clinics across the U.S. that they’re now testing for approximately 2 percent of all births in the country every year. While CEO Ramji Srinivasan didn’t want to comment for this story, you could expect that gene testing companies which don’t currently offer tests linked to

Source: http://feedproxy.google.com/~r/Techcrunch/~3/yMF0R6s5R7Q/

tony robbins bon iver abraham lincoln vampire hunter their eyes were watching god lara logan manu ginobili sports illustrated swimsuit 2012